VisiCELL Medical Inc. With a dedicated team of passionate scientists, engineers, and radiologists, VisiCELL Medical is committed to accelerating the development and introduction of cell-based therapies for devastating diseases like Parkinson’s, Alzheimer’s, stroke, and cancer. The company's innovative technology includes a suite of imaging tools that empower scientists and clinicians to evaluate cell therapy in a faster, more cost-effective way.

These tools enable researchers to assess treatment safety and effectiveness from the pre-clinical stage all the way through clinical trials. By effectively tracking therapeutic cells in subjects, VisiCELL Medical's technology shortens the time it takes to bring these essential therapies to market. Key to their success is their clinically applicable imaging tool, which has been further developed into an all-in-one solution applicable to different immune and stem cell types.

Additionally, based on specific disease models, they have expanded the technology for dual imaging modality. Led by Co-Founders Mya Thu and Amil Gentili, along with Chief Science Officer Mark Stolowitz, the VisiCELL Medical team brings decades of expertise in nanomaterials, stem cell imaging, medical device engineering, and radiology. With a strong focus on clinical applicability and continuity from pre-clinical to clinical trials, VisiCELL Medical aims to transform the development and market introduction of biopharmaceutical products.

Supported by a distinguished Advisory Board, including leading experts and innovators in the field, VisiCELL Medical is at the forefront of cell-based therapy advancements. To stay updated with the latest developments from VisiCELL Medical, visit their News page. Join VisiCELL Medical in their mission to revolutionize cell-based therapy and provide hope to patients in need